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Sumrrlary 
T  cells play a major role in the development of insulin-dependent diabetes mellitus (IDDM) 
in nonobese diabetic (NOD) mice. Administration of interleukin 12 (IL-12), a key cytokine which 
guides the development of T helper type 1 (Thl) CD4 +~ T cells, induces rapid onset of IDDM 
in NOD, but not in BALB/c mice. Histologically,  IL-12 administration induces massive infiltration 
of lymphoid cells,  mostly T  cells,  in  the pancreatic islets  of NOD  mice.  CD4 + pancreas- 
infiltrating T  cells, after activation by insolubilized anti T  cell receptor antibody, secrete high 
levels of interferon 3/and low levels of IL-4. Therefore, IL-12 administration accelerates IDDM 
development in genetically susceptible NOD mice, and this correlates with increased Thl cytokine 
production by islet-infiltrating cells. These results hold implications for the pathogenesis, and 
possibly for the therapy of IDDM  and of other Thl cell-mediated autoimmune diseases. 
B 
ased on the repertoire of lymphokine production, mouse 
(1) and human (2) CD4 + T cells can be subdivided into 
two subsets, Thl and Th2, characterized by secretion of IFN-3' 
and IL-4, respectively. The generation of Thl and Th2 subsets 
is influenced by the cytokines present during the initial phase 
of the immune response, and a major role is played by IL-12 
and IL-4 (3, 4). IL-12, a heterodimeric cytokine (5, 6) pro- 
duced by activated monocytes and B cells (7), promotes Thl 
cell development. It also enhances proliferation and cytolytic 
activity of NK and T  cells (8),  and stimulates production 
of IFN-3, by these cell types (9).  IFN-qr  appears  to play a 
role in the development of insulin-dependent diabetes mel- 
litus (IDDM), as demonstrated by the prevention of disease 
by administration of anti-IFN-3, mAb to nonobese diabetic 
(NOD) mice (10,  11), or by IDDM induction in mice ex- 
pressing genes encoding IFN-y under the control of the in- 
sulin promoter (12). It has been proposed that the patholog- 
ical immune response of NOD mice to islet/~ cells is initiated 
by CD4 + T  cells that recognize glutamic acid decarboxy- 
lase (13, 14), and splenic CD4 + T cells from NOD mice se- 
crete IFN-3' when stimulated with this enzyme (13). Con- 
versely, the Th2-derived lymphokines IL-4 and IL-10 appear 
to inhibit progression to IDDM in NOD mice (15-17). These 
findings suggest that T cells that recognize pancreatic B cell 
antigens cause IDDM only if they develop into Thl cells. 
To test this assumption, we treated prediabetic NOD mice 
with IL-12, which has been shown to induce the develop- 
ment of IFN-3,-producing Thl cells in vitro (18,  19) and 
in vivo (20).  Results in the present paper demonstrate that 
administration of IL-12 to prediabetic NOD female mice in- 
duces rapid onset of IDDM. This is associated with enhanced 
production of Thl-type cytokines by islet-infiltrating lym- 
phocytes, and with selective  destruction of islet B cells. 
Materials  and Methods 
Mice.  10-wk-old female BALB/c mice were obtained  from 
Charles River (Calco, Italy). NOD/Lt mice from The  Jackson Lab- 
oratory (Bar Harbor,  ME) were bred and kept in conventional 
housing conditions in our animal facility. Mice were diagnosed di- 
abetic after two sequential measurements of blood glucose levels 
>200 rag/d1. The incidence of IDDM in NOD female mice from 
our colony was '~60%. 
Recombinant Mouse IL-12.  Recombinant mouse IL-12 was pro- 
duced in serum-free medium by transfected CHO cells and purified 
by sequential chromatography, as described (21). The IL-12 used 
in this study was >95% pure, as assessed by SDS-PAGE analysis, 
and the endotoxin content was <5 endotoxin U/rag IL-12, as de- 
termined by the Limulus amebocyte assay. IL-12 was diluted in PBS 
containing 1% syngenic mouse serum or 100/~g/ml mouse serum 
albumin (Sigma Chemical Co., St. Louis, MO) and injected in- 
traperitoneally in a 0.2-ml volume. IL-12 has a half-life in mice 
of -5 h (Gately, M., and R. Nadeau, unpublished observations). 
Isolation of Pancreas-infiltrating Cells.  Individual pancreata were 
perfused with PBS. After removal of all visible pancreatic lymph 
nodes, the pancreata were digested in HBSS containing 5 mg/ml 
collagenase IV and 2.5 mg/ml DNase (Sigma Chemical Co.), by 
shaking (200 rpm) at 37~  for 12 min. Single cell suspensions  were 
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5% FCS and removal of the aggregates by settling 5 min on ice. 
Aggregates were further digested with collagenase IV (2.5 mg/ml) 
and DNase (1.25 mg/ml) for 5 min. Single cell suspensions from 
three to four mice were pooled, washed three times, and CD4 + 
and CD8 + cells were sorted by positive selection  on Mini-MACS  | 
(Miltenyi  Biotec  Inc.,  Sunnyvale,  CA).  The  mean  number  of 
CD4 + and CD8 + cells recovered per pancreas in three separate ex- 
periments was, respectively,  51 and 20  x  104 for vehicle-injected 
mice, 82  and 66  x  104 for IL-12-treated littermates. 
Induction of Lymphokine Production.  CD4 §  and  CD8 +  cells 
were  cultured  (2.5  x  105  cells/well)  in  96-well  round  bottom 
plates coated with 5/~g/ml anti-TCR mAb (American Type Cul- 
ture Collection  [ATCC] HB 218; Rockville, MD) in  serum-free 
HL-1 medium (Ventrex Laboratories, Portland, ME) supplemented 
with 2 mM r-glutamine and 50/~g/ml gentamicin (Sigma Chem- 
ical Co.).  Supernatants were collected after 48 h  of culture.  Sera 
were collected ~15 h after the last IL-12 injection and assayed for 
ELISA for circulating IFN-3,. 
Immunohistology.  For hematoxylin and eosin staining,  pancreata 
were fixed  in  10%  formalin and embedded in paraffin.  For im- 
munoperoxidase staining, pancreata were snap-frozen in Tissue-Tek 
(Miles Laboratories Inc., Elkhart, IN), and consecutive 5 #m sec- 
tions  stained  for 45  min  with  rabbit  anti-glucagon  and  mouse 
anti-insulin antibodies (Ortho Diagnostic Systems, Raritan, NJ). 
After washing, sections were incubated for 30 rain with secondary 
antibodies conjugated to horseradish peroxidase, which was visual- 
ized using 3 amino-9 ethyl-carbazole (AEC, Sigma Chemical Co.) 
as chromogen and hematoxylin as counterstain. In addition, pan- 
creas cryostat sections were stained by biotinylated mAb directed 
against CD4, CD8, B220 (PharMingen, San Diego, CA), p150/90 
leucocyte B2 integrin (N418, ATCC), and I-Ag  7 (10.3.62,  ATCC), 
followed by streptavidin-peroxidase conjugate. AEC was used as 
a chromogen and hematoxylin as a counterstain. 
Cytokine Assays.  IFN-3/and IL-4 concentrations were deter- 
mined by ELISA using,  respectively,  mAb AN-18.17.24  (22)  or 
BVD4-1D11 (PharMingen) for capture, and peroxidase-conjugated 
XMG1.2 (23) or biotinylated BVD6-24G2 (PharMingen) followed 
by avidin-peroxidase  (Sigma Chemical Co.) for detection. The sub- 
strate was 3,Y-5,5'-tetramethylbenzidine (Fluka Chemie AG, Buchs, 
Switzerland). Dilutions of culture supernatant or serum were as- 
sayed in the linear portion of the dose-response curve. Standard 
curves were generated in  each assay using purified recombinant 
mouse IFN-3, or IL-4. 
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Figure  2.  Insulitis  is observed in NOD but not in BALB/c mice after 
administration of Ib12. Islets from a 10-wk-old BALB/c mouse after 32 
injections of IL-12  are intact (2t). In contrast, islets from a 10-wk-old  NOD 
mouse after 20 injections of Ib12 show a severe  mononuclear cell infiltra- 
tion  (B). x250. 
Results and Discussion 
Administration of recombinant mouse IL-12 to 8-10-wk-old 
prediabetic NOD  female mice induced rapid onset of IDDM 
(Fig. 1). Overt diabetes began after about 10 IL-12 injections, 
and after 30 injections it was present in  100%  of the mice. 
The same treatment did not induce IDDM in BALB/c mice. 
In the  NOD  female littermates  injected  with  vehicle only 
(PBS-1% normal NOD  serum), IDDM began only at 15 wk 
of age, and by week 40, hyperglycemia was present in 55% 
of the  mice. 
Histological analysis of pancreatic sections revealed insu- 
litis in NOD  mice injected with IL-12, but not in BALB/c 
mice, even after 32 injections of IL-12 (Fig.  2).  The normal 
appearance of pancreatic islets and the absence of IDDM in 
BALB/c mice indicates a lack of direct toxic effects of IL-12 
administration on islet B ceils in vivo. Quantification of islet 
infiltrates showed a higher score in NOD  mice injected with 
IL-12 as compared with those injected with vehicle only (not 
Figure  1.  Accderation of IDDM onset by IL-12  administration to NOD 
mice. 10 female  NOD/Lt prediabetic  mice (8-10 wk old, randomized from 
four different  litters) were injected daily  with 0.3 #g i.p. recombinant  mouse 
I1.-12 for the first 7 d, then with 0.15 #g for the following 24 d (Q), or 
with vehicle (PBS containing  1% NOD serum) only (O). As control, 
10 BALB/c female mice (10 wk old) received the same IL-12 treatment 
(A). Four other independent experiments, performed with 10-14-wbold 
NOD females  injected with 0.15 #g IIr  daily, gave  similar  results, IDDM 
onset starting after 5-10 Ib12 injections. 
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in NOD mice injected with II:12. Pan- 
creas from a 10-wk-old  NOD female 
mouse  injected  14 times with vehicle 
only displays insulitis, but glucagon- (A) 
and insulin- (B) containing islet cells are 
well represented. In contrast, the NOD 
littermate injected 14 times with I1:12 
(0.15 #g/day) had disorganized but rel- 
atively normal numbers  of glucagon- 
containing  cells (C),  whereas  insulin- 
containing  cells (/9) are  absent.  The 
latter  finding  correlates  with  hyper- 
glycemia (>500  mg/dl) at the time of 
pancreas removal.  ￿ 
Figure  4.  lmmunostaining of pan- 
creas-infiltrating cells in NOD mice in- 
jected with I1:12. Massive infiltration 
containing  high  numbers  of  CD4 + 
(A), and CD8 + (B) T cells is observed 
in the pancreas from a 10 wk-old NOD 
female  injected 14 times with II:12 (0.15 
/zg/day). An infiltrated  islet from this 
mouse  shows  abundant  B220 +  (D), 
class  II +  (E)  and  N418 +  (F)  cells. 
N418+ cells are also present in the exo- 
crine pancreas (C). A-C,  x 200; D-F, 
x400. 
819  Trembleau  et al.  Brief Definitive  Report Table  1.  Production of IFN-'y and IL-4  by Pancreas-infiltrating CD4 + or CD8 + T  Cells from NOD Mice 
IFN-T  II.-4 
Pancreas-infiltrating cells  Pancreas-infiltrating cells 
Serum  CD4 §  CD8 *  CD4 +  CD8 + 
D~7  D~14  -  ~-~R  -  a-~R  -  ~-~R  -  a-~R 
Vehicle  <5  <5  <(15  9,241  <(15  9,200  148  2,268  50  107 
IL-12  303  125  <(15  37,226  <(15  17,721  59  471  <(15  <(15 
Pancreas-infiltrating  CD4 + or CD8 + cells from 9-wk old NOD mice injected  with IL-12 (0.15 #g/mouse/d  for 13-14 d) or with vehicle only were 
stimulated with insolubilized  anti-TCR  mAb (5 #g/ml). After 48 h of culture, IFN-'y  and 1I.-4 production (pg/ml) were quantified  by ELISA. Sera 
were assayed  by ELISA for circulating IFN-3' (pg/ml). Results are means of two to four experiments. 
shown). IL-12-treated mice had profoundly reduced numbers 
of insulin-secreting fl cells, whereas glucagon-producing cells 
were not affected (Fig. 3). These results demonstrate that the 
diabetes  induced by IL-12  administration is of an autoim- 
mune nature, selectively destroying insulin-producing ~ cells. 
Surface markers of pancreas-infiltrating cells were analyzed 
by immunohistochemistry and representative sections from 
IL-12-injected NOD mice are shown in Fig. 4. Islet infiltrates 
are dominated by CD4 + and CD8 + T  cells and tend to ex- 
tend into the exocrine pancreas (A and B). IL-12 administra- 
tion induces an increase in the number of CD4 + cells, and 
a marked increase of CD8 + cells (see Materials and Methods). 
The infiltrates contain class II + cells (E) which include B 
cells (D) and N418 + cells (F).  The latter cells are abundant 
also in the exocrine pancreas (C). The N418 antibody recog- 
nizes CD11c,  an integrin expressed on dendritic cells and at 
a low level on macrophages in normal lymphoid tissues (24). 
Thus, all the cell types necessary  for an immune response 
are present in the islets  of IL-12-treated mice. 
To determine whether IL-12 administration induces Thl 
cells we tested IFN-'y and IL-4 production by islet-infiltrating 
T cells after stimulation by insolubilized anti-TCR mAb. Islet- 
infiltrating CD4 + cells from NOD mice injected with IL-12 
produced high amounts of IFN-% about fourfold higher than 
T  cells from NOD mice injected with vehicle only (Table 
1). Conversely, IL-4 production was decreased in pancreas- 
infiltrating CD4 + cells from IL-12 treated as compared with 
control NOD mice. These results indicate that CD4 + cells 
infiltrating the lesion site in IL-12-injected NOD mice mostly 
exhibit  a  Thl  lymphokine  profile.  Pancreas-infiltrating 
CD8 + cells, which participate  in IDDM induction (25), also 
produce high levels of IFN-3, and little IL-4, indicating a Thl- 
like phenotype (26). IFN-y could also be detected in the serum 
of NOD mice injected with IL-12 (Table 1). In agreement 
with previous results, it peaked 1 wk after beginning of IL-12 
administration (21). 
These results show that administration of IL-12 accelerates 
the onset of IDDM and induces disease in all NOD female 
mice tested, whereas only ~60% of control littermates even- 
tually develop  IDDM. Acceleration of IDDM is accompa- 
nied by expansion of Thl cells and by selective destruction 
of islet fl cells, suggesting a causal link between IL-12, Thl 
cell induction, and development of IDDM. The spontaneous 
development of IDDM may also involve  IL-12-dependent 
generation of Thl cells. This possibility will be tested by ad- 
ministration of IL-12 antagonists (27) to NOD mice, a poten- 
tial therapeutic approach for the treatment of IDDM and of 
other Thl cell-mediated autoimmune diseases. The present 
results also suggest that IL-12, a possible therapeutic agent 
against tumors (28) and infectious diseases (29),  should be 
administered cautiously to patients with Thl-mediated au- 
toimmune diseases, or with a known predisposition to them. 
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